Novo Nordisk Q3 2026 slides: sales recover, outlook raised on GLP-1 growth
Novo Nordisk released its Q3 2026 financial results on November 4, 2026, showcasing a 4% growth in adjusted sales at constant exchange rates, marking a 27% increase in operating profit to DKK 31.7 billion. The company highlighted the strong performance of its GLP-1 products in driving this growth, with obesity sales up 22% and diabetes sales down 7%.
Novo Nordisk added 1.3 million net patients to its diabetes and obesity treatments in Q3 2026, bringing the total global patient count to approximately 47.8 million. The GLP-1 franchise remains a key growth driver, with Wegovy and Ozempic leading market share in international markets. The company's R&D efforts are also progressing, with seven first-human-dose milestones achieved and ten phase 3 programs underway. Novo Nordisk anticipates regulatory decisions for new therapies in Q4 2026 and early 2027.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
